期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人表皮生长因子受体2在胃癌中的表达及临床意义 被引量：6

Expression and clinical significance of Her2 in gastric cancer
下载PDF
导出
摘要 人表皮生长因子受体(Her)2是一种具有酪氨酸激酶活性的跨膜糖蛋白,其表达与肿瘤的形成、恶性程度及预后密切相关。Her2高表达是胃癌预后不良的标记物之一,针对Her2的分子靶向药物曲妥珠单抗和拉帕替尼与化疗药物联合治疗胃癌的初步临床研究均获得显著效果。本文综述Her2在胃癌中的表达及临床意义。 Human epidermal growth factor receptor （Her）2 is a kind of trans-membrane glycoprotein with tyrosine kinase activity. Its expression is closely related with tumor formation, malignancy grade and prognosis. Her2 overexpression is a marker of poor prognosis in gastric cancer. As molecular targeted drugs against Her2, trastuzumab and lapatinib have shown good clinical results when they combine with chemotherapy to treat gastric cancer. This review focuses on the expression and clinical significance.
作者 倪国英 朱松明
机构地区 上海交通大学医学院附属新华医院崇明分院肿瘤科 上海交通大学医学院附属新华医院崇明分院普外科
出处 《世界临床药物》 CAS 2011年第8期499-502,共4页 World Clinical Drug
基金 上海交通大学医学院科技基金项目(项目编号:09XJ22002)
关键词 胃癌 靶向治疗 曲多单抗 拉帕替尼 人表皮生长因子受体2 gastric cancer targeted therapy trastuzumab lapatinib Her2
分类号 R735.2 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献27

  • 1宋岩,黄镜,王金万.HER2/neu基因扩增和蛋白表达与晚期胃癌患者预后的关系[J].癌症,2010,29(1):76-81. 被引量：25
  • 2陈斌,罗荣城,崔斐,钱新宇.胃癌HER-2/neu基因表达与预后的相关性[J].南方医科大学学报,2006,26(3):344-347. 被引量：44
  • 3Guan Zhen Yu,Ying Chen,Jie Jun Wang.Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance[J]. Journal of Cancer Research and Clinical Oncology . 2009 (10)
  • 4Xiu Li Zhang,Yun Sheng Yang,Dong Ping Xu,Jian Hui Qu,Ming Zhou Guo,Yan Gong,Jin Huang.Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer[J]. World Journal of Surgery . 2009 (10)
  • 5Kaori Fujimoto-Ouchi,Fumiko Sekiguchi,Hideyuki Yasuno,Yoichiro Moriya,Kazushige Mori,Yutaka Tanaka.Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models[J]. Cancer Chemotherapy and Pharmacology . 2007 (6)
  • 6Dong Il Park,Jung Won Yun,Jung Ho Park,Suk Joong Oh,Hong Joo Kim,Yong Kyun Cho,Chong Il Sohn,Woo Kyu Jeon,Byung Ik Kim,Chang Hak Yoo,Byung Ho Son,Eun Yoon Cho,Seoung Wan Chae,Eo-Jin Kim,Jin Hee Sohn,Seung Ho Ryu,Antonia R. Sepulveda.HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer[J]. Digestive Diseases and Sciences . 2006 (8)
  • 7Günter Finkenzeller,Karin Weindel,Wolfgang Zimmermann,Gunnar Westin,Dieter Marmé.Activated Neu/ErbB-2 Induces Expression of the Vascular Endothelial Growth Factor Gene by Functional Activation of the Transcription Factor Sp 1[J]. Angiogenesis . 2004 (1)
  • 8Ismail HM,Moneer M,El-Baradie M,et al.Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53oncoproteins in gastric carcinoma using tissue microarray. J Egypt Natl Canc Inst . 2007
  • 9Marx AH,Tharun L,Muth J,et al.HER-2amplification is highly homogenous in gastric cancer. Human Pathology . 2009
  • 10Matsui Y,Inomata M,Tojigamori M,et al.Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2antibody in amurine model. International Journal of Oncology . 2005

二级参考文献31

  • 1李宁 祝庆孚.C－erbB-2和P53基因产物增强表达与胃癌生物学行为和预后关系[J].中华外科杂志,1994,32(9):558-558.
  • 2Ross JS, Fletcher JA. HER-2/neu (cerb-B2) gene and protein in breast cancer [J]. Am J Chin Pathol, 1999,112 (Suppl 1 ) : S53-S67.
  • 3Menard S, Casalini P, Campiglio M, et al. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer [J]. Ann Oncol, 2001,12(Suppl 1) :S15-S19.
  • 4Varis A, Zaika A, Puolakkainen P, el hi. Coamplified and overexpressed genes at erbB2 locus in gastric cancer [J]. Int J Cancer, 2004, 109(4) : 548-553.
  • 5Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer [J]. Dig Dis Sci, 2006,51(8) : 1371-1379.
  • 6Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction [ J ]. Hum Pathol, 2007,38 (9) : 1386-1393.
  • 7Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c- erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients [ J ]. Cancer, 1993,72 ( 11 ) : 3179-3184.
  • 8Mizutani T, Onda M, Tokunaga A, et al. Relationship of C- erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer [J]. Cancer, 1993,72 ( 2 ) : 2033-2038.
  • 9Yano T, Ochiai A, Doi T, et al. Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit [J]. J Clin Oncol, 2004,22: 14S (Abstr 4053).
  • 10Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message [ J ]. J Clin Oncol, 2001,19 ( 10 ) : 2714-2721.

共引文献62

同被引文献57

  • 1陈川（综述）,俞德超（审阅）,滕理送（审阅）.以VEGF/VEGFR为靶点的抗肿瘤药物的研究进展[J].中国肿瘤生物治疗杂志,2007,14(3):291-295. 被引量：25
  • 2陈斌,罗荣城,崔斐,等.胃癌Her-2/neu基因表达与预后的相关性[J].南方医科大学学报,2006,26(3):344-7.
  • 3Enzinger PC, Ryan DP, Regan EM, et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer[J].J Clin Oncol, 2008, 26: 4552.
  • 4Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combinationwith chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial [J].J Clin Oncol, 2012, 30(17): 2119-2127.
  • 5Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study[J]. J Clin Oncol, 2011, 29(30): 3968-3976.
  • 6Trotti A, Colevas AD, Setser A, et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment [J]. Semin Radiat Oncol, 2003, 13(3): 176-181.
  • 7Gretschel S, Astrosini Ch, Vieth M, et al. Markers of tumour angiogenesis and tumour cells in bone marrow in gastric cancer patients[J]. EurJ Surg Oncol, 2008, 34(6): 642-427.
  • 8Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma[J]. J Clin Oncol, 2006, 24(33): 5201-5206.
  • 9Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGe)[J]. J Clin O ncol, 2010, 28(18s):LBA4007.
  • 10Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial[J]. Ann Oncol, 2009, 20(4): 666-673.

引证文献6

二级引证文献32

世界临床药物
2011年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部